Prognostic factors for breast cancer brain metastasis and primary construction of a prediction model

Siyi XIONG; Andi WAN; Cheng WANG; Guozhi ZHANG; Ling ZHONG; Xuanni TAN; Xiaowei QI; Yi ZHANG

doi:10.16016/j.2097-0927.202307011

您当前的位置：

首页 >

文章列表页 >

Prognostic factors for breast cancer brain metastasis and primary construction of a prediction model

Clinical Medicine | 更新时间：2026-01-09

- Prognostic factors for breast cancer brain metastasis and primary construction of a prediction model
- Journal of Army Medical University Vol. 45, Issue 18, Pages: 1974-1982(2023)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)第一附属医院乳腺甲状腺外科
- 作者简介：
- 基金信息：
  
  the Chongqing Talent Program of Chongqing Health Commission(CQYC20210303406)
- DOI：10.16016/j.2097-0927.202307011
  CLC： R195.4;R737.31;R739.41
- Received：02 July 2023，
  
  Revised：2023-07-12，
  
  Published：30 September 2023
- 稿件说明：
移动端阅览
Siyi XIONG, Andi WAN, Cheng WANG, et al. Prognostic factors for breast cancer brain metastasis and primary construction of a prediction model[J]. Journal of Army Medical University, 2023, 45(18): 1974-1982.
DOI：

Siyi XIONG, Andi WAN, Cheng WANG, et al. Prognostic factors for breast cancer brain metastasis and primary construction of a prediction model[J]. Journal of Army Medical University, 2023, 45(18): 1974-1982. DOI： 10.16016/j.2097-0927.202307011.

摘要

目的

探讨乳腺癌脑转移(breast cancer brain metastasis，BCBM)患者预后影响因素，并构建和验证可评估BCBM患者预后的预测模型。

方法

采用病例-对照研究设计方案。筛选“监测、流行病学和最终结果数据库”(Surveillance，Epidemiology，and End Results，SEER)2016-2020年BCBM患者病例资料1 133例，按照7 ∶3比例随机分配到训练集(793例)和内部验证集(340例)。通过单因素、多因素Cox回归分析确定预后影响因素，并构建列线图(Nomogram图)预测模型。以C指数、ROC曲线和校准曲线对列线图的区分度、预测效能和校准度进行评价。采用陆军军医大学第一附属医院乳腺甲状腺外科2004-2019年收治的BCBM患者(73例)对列线图预测模型进行外部验证。

结果

多因素Cox回归分析确定了年龄、分子分型、手术、放疗、化疗、肺转移、肝转移为独立影响因素(

0.05)，并据此建立列线图预后预测模型。SEER数据库训练集、内部验证集以及本院外部验证集的C指数分别为0.720(95%

：0.674~0.766)、0.705(95%

：0.633~0.777)、0.667(95%

：0.610~0.724)。训练集ROC曲线显示，列线图可以准确预测BCBM患者半年(AUC=0.793)、1年(AUC=0.759)和2年(AUC= 0.724)的生存概率。校准曲线可见预测值与实际观察值具有良好的一致性。

结论

年龄、分子分型、手术、放疗、化疗、肺转移、肝转移是BCBM预后的独立影响因素；据此构建的Nomogram图能有效预测BCBM患者半年、1年和2年的生存概率。

Abstract

Objective

To investigate the prognostic factors of breast cancer brain metastasis (BCBM)

and to construct and validate a prediction model for prognosis of BCBM patients.

Methods

A case-control trial was designed and conducted in this study. A total of 1 133 BCBM patients were screened out from the Surveillance

Epidemiology

and End Results (SEER) database from 2016 to 2020

and were randomly assigned to a training set (

=793) and an internal validation set (

=340) at a ratio of 7 ∶3. The prognostic factors were determined with univariate and multivariate Cox regression analyses

and a nomogram prediction model was constructed. The discrimination

prediction and calibration of the nomograms were evaluated by C-index

receiver operating characteristic (ROC) curve and calibration curve. External validation of the nomogram prediction model was performed in 73 BCBM patients admitted to our hospital

from 2004 to 2019.

Results

Multivariate Cox regression analysis revealed that age

molecular type

surgery

radiotherapy

chemotherapy

lung metastasis and liver metastasis were identified as independent factors (

0.05)

and a prediction model of the nomogram was thus established. The C-index of the SEER training set

internal validation set and external validation set were 0.720 (95%

: 0.674~0.766)

0.705 (95%

: 0.633~0.777) and 0.667 (95%

: 0.610~0.724)

respectively. The ROC curve of the training set showed that our nomogram could accurately predict the survival rate of BCBM patients at 6 months (AUC=0.793)

and 1 (AUC=0.759) and 2 years (AUC=0.724). The predictive values of the calibration curve are in good agreement with the observed values.

Conclusion

Age

molecular type

surgery

radiotherapy

chemotherapy

and lung and liver metastases are independent prognostic factors of BCBM. Our constructed nomogram can effectively predict the 6-month

1-year and 2-year survival probability of BCBM patients.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

BROSNAN E M, ANDERS C K. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies[J]. Ann Transl Med, 2018, 6(9): 163. DOI: 10.21037/atm.2018.04.35.

LIN N U, AMIRI-KORDESTANI L, PALMIERI D, et al . CNS metastases in breast cancer: old challenge, new frontiers[J ] . Clin Cancer Res, 2013, 19(23): 6404-6418. DOI: 10.1158/1078-0432.ccr-13-0790.

MARTIN A M, CAGNEY D N, CATALANO P J, et al . Brain metastases in newly diagnosed breast cancer: a population-based study[J ] . JAMA Oncol, 2017, 3(8): 1069-1077. DOI: 10.1001/jamaoncol.2017.0001.

KIM Y J, KIM J S, KIM I A. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database[J]. J Cancer Res Clin Oncol, 2018, 144(9): 1803-1816. DOI: 10.1007/s00432-018-2697-2.

XIONG S Y, TAN X N, WU X J, et al . Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis[J ] . Ther Adv Med Oncol, 2023, 15: 17588359231165976. DOI: 10.1177/17588359231165976.

NAKHJAVANI M, SAMARASINGHE R M, SHIGDAR S. Triple-negative breast cancer brain metastasis: an update on druggable targets, current clinical trials, and future treatment options[J]. Drug Discov Today, 2022, 27(5): 1298-1314. DOI: 10.1016/j.drudis.2022.01.010.

HUANG Z, SUN B, WU S K, et al . A nomogram for predicting survival in patients with breast cancer brain metastas is[J ] . Oncol Lett, 2018, 15(5): 7090-7096. DOI: 10.3892/ol.2018.8259.

XIONG Y, CAO H, ZHANG Y Q, et al . Nomogram-predicted survival of breast cancer brain metastasis: a SEER-based population study[J ] . World Neurosurg, 2019, 128: e823-e834. DOI: 10.1016/j.wneu.2019.04.262.

DOLL K M, RADEMAKER A, SOSA J A. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database[J]. JAMA Surg, 2018, 153(6): 588-589. DOI: 10.1001/jamasurg.2018.0501.

BAILLEUX C, EBERST L, BACHELOT T. Treatment strategies for breast cancer brain metastases[J]. Br J Cancer, 2021, 124(1): 142-155. DOI: 10.1038/s41416-020-01175-y.

CORTI C, ANTONARELLI G, CRISCITIELLO C, et al . Targeting brain metastases in breast cancer[J ] . Cancer Treat Rev, 2022, 103: 102324. DOI: 10.1016/j.ctrv.2021.102324.

CARSTEN, NIEDER. Prognostic and predictive factors in patients with brain metastases from solid tumors: a review of published nomograms[J]. Crit Rev Oncol, 2018, 126: 13-18. DOI: 10.1016/j.critrevonc.2018.03.018.

VAN ZEE K J, MANASSEH D M E, BEVILACQUA J L B, et al . A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy[J ] . Ann Surg Oncol, 2003, 10(10): 1140-1151. DOI: 10.1245/ASO.2003.03.015.

MOREAU J T, HANKINSON T C, BAILLET S, et al . Individual-patient prediction of meningioma malignancy and survival using the Surveillance, Epidemiology, and End Results database[J ] . NPJ Digit Med, 2020, 3: 12. DOI: 10.1038/s41746-020-0219-5.

AHN H K, LEE S, PARK Y H, et al . Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram[J ] . Neuro-oncology, 2012, 14(8): 1105-1113. DOI: 10.1093/neuonc/nos137.

NIE Y, YING B C, LU Z N, et al . Predicting survival and prognosis of postoperative breast cancer brain metastasis: a population-based retrospective analysis[J ] . Chin Med J (Engl), 2023, 136(14): 1699-1707. DOI: 10.1097/CM9.0000000000002674.

LI C F, LIU M J, ZHANG Y B, et al . Novel models by machine learning to predict prognosis of breast cancer brain metastases[J ] . J Trans l Med, 2023, 21(1): 404. DOI: 10.1186/s12967-023-04277-2.

BALACHANDRAN V P, GONEN M, SMITH J J, et al . Nomograms in oncology: more than meets the eye[J ] . Lancet Oncol, 2015, 16(4): e173-e180. DOI: 10.1016/S1470-2045(14)71116-7.

RAMSPEK C L, JAGER K J, DEKKER F W, et al . External validation of prognostic models: what, why, how, when and where?[J ] . Clin Kidney J, 2021, 14(1): 49-58. DOI: 10.1093/ckj/sfaa188.

MARKO N F, XU Z Y, GAO T M, et al . Predicting survival in women with breast cancer and brain metastasis[J ] . Cancer, 2012, 118(15): 3749-3757. DOI: 10.1002/cncr.26716.

DESANTIS C E, LIN C C, MARIOTTO A B, et al . Cancer treatment and survivorship statistics, 2014[J ] . CA Cancer J Clin, 2014, 64(4): 252-271. DOI: 10.3322/caac.21235.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Construction and validation of prediction model for cervical cancer recurrence based on systemic inflammation response index and clinicopathological parameters

Outcomes of pregnancy-associated breast cancer: a Meta-analysis

Expression and significance of human defensin-alpha1-3 in breast cancer

Related Author

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

GUAN Tinghong

GONG Chunxia

TU Yuan

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gynecology and Obstetrics， the First Affiliated Hospital of Chongqing Medical University

Department of Gynecology and Obstetrics， Women and Children’s Hospital Affiliated to Chongqing Medical University

First Department of General Surgery, Yongchuan Hospital, Chongqing Medical University

The First Clinical Medical College， Lanzhou University

⁰